Frances Hackman
Publications by Year
Research Areas
SARS-CoV-2 and COVID-19 Research, HIV/AIDS drug development and treatment, Asthma and respiratory diseases, HIV Research and Treatment, Computational Drug Discovery Methods
Most-Cited Works
- → Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 Infection(2010)265 cited
- → Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: An international collaborative effort(2018)234 cited
- → Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir(2022)153 cited
- → The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms(2011)58 cited
- → Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients(2009)43 cited
- → Metabolism and Excretion of Nirmatrelvir in Humans Using Quantitative Fluorine Nuclear Magnetic Resonance Spectroscopy: A Novel Approach for Accelerating Drug Development(2022)32 cited
- → Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects(2008)28 cited
- → Add-on histamine receptor-3 antagonist for allergic rhinitis: a double blind randomized crossover trial using the environmental exposure unit(2014)22 cited
- → Safety, Tolerability, and Pharmacokinetics of Intravenous Doses of PF‐07304814, a Phosphate Prodrug Protease Inhibitor for the Treatment of SARS‐CoV‐2, in Healthy Adult Participants(2022)12 cited
- → Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19(2023)10 cited